Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer
Authors:
- 1 December 2007
- journal article
- review article
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 4 (12) , 677-687
Abstract
Molecular biomarkers can serve as useful diagnostic markers, as prognostic markers for predicting clinical behavior, or as targets for new therapeutic strategies. Application of expression microarray technology, which allows the expression of all or most of the genes in the human genome to be analyzed simultaneously, has dramatically enhanced the discovery of prostate cancer biomarkers. The diagnostic markers identified include AMACR (α-methylacyl CoA racemase), a protein that has already been translated into clinical use as an aid in distinguishing prostate cancer from benign disease. Individual genes, such as the polycomb gene EZH2 whose expression indicates poor survival, have been identified. The power of microarray technology is that it has allowed the identification of gene signatures (each composed of multiple genes) that might provide improved prediction of clinical outcomes in human prostate cancer. The development of a new method for analyzing expression microarray data, called COPA, has led to the discovery of TMPRSS2–ERG gene fusion involvement in the development of prostate cancer, while expression analysis of castration-resistant prostate cancer has suggested the use of novel therapeutic approaches for advanced disease. Despite these successes, there are limitations in the application of microarray technology to prostate cancer; for example, unlike with other cancers, this approach has failed to provide a consistent unsupervised classification of the disease. Overcoming the reasons for these failures represents a major challenge for future research endeavors.Keywords
This publication has 68 references indexed in Scilit:
- Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancerOncogene, 2007
- Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysisOncogene, 2007
- A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancersNature Genetics, 2006
- Thousands of samples are needed to generate a robust gene list for predicting outcome in cancerProceedings of the National Academy of Sciences, 2006
- MicroRNA expression profiles classify human cancersNature, 2005
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- A molecular signature of metastasis in primary solid tumorsNature Genetics, 2002
- Delineation of prognostic biomarkers in prostate cancerNature, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000